A prospective, randomized placebo-controlled study was undertaken to compare the effects on heart rate and blood pressure during surgery and on the incidence of nausea, vomiting and headache after surgery of IM prochlorperazine 0.2 mg.kg -1 , IV prochlorperazine 0.1 mg.kg -1 and IV ondansetron 0.06 mg.kg -1 given at induction of general anaesthesia to patients undergoing septorhinoplasty.
The Department of Anaesthesia of the Riyadh Armed Forces Hospital comprises 38 anaesthetists, 20 of whom are Fellows of British Colleges, three have equivalent European or Middle-Eastern certificates, six have Egyptian specialist qualifications and nine are undergoing training in anaesthesia. An opinion survey revealed that (1) one member considered omission of an antiemetic as routine adjuvant to the drugs administered during anaesthesia as unethical, and (2) the efficacy expected of any antiemetic to warrant such routine use was a reduction by 46% (SD10%; range 4-96%) from the base rate of nausea or vomiting after any particular type of surgery.
Ondansetron is a derivative of cocaine and metoclopramide which exerts an antiemetic effect devoid of cholinergic, adrenergic, dopaminergic or histamine actions by selective blockade of 5 hydroxytryptamine subtype 3 (5-HT 3 ) receptors 1 . It has a half-life of 3.5 to 5.5 hours after IV administration 2 , is superior to metoclopramide 3 and droperidol 4 as prophylactic antiemetic in the perioperative period but, by virtue of its mode of action, may increase the incidence of postoperative headache 5, 6 . Prochlorperazine is a phenothiazine derivative with a half-life of 23 hours after IV administration 7 , which exerts an antiemetic effect via dopaminergic blockade. It is licensed in North America for parenteral injection in adults via the IM and IV routes (recommended dose 5-10 mg), in Europe for parenteral administration by IM injection only (recommended dose 12.5 mg) 8 , and is considered to be more efficacious than metoclopramide and droperidol in anaesthetic practice 9 . However, prochlorperazine may cause extrapyramidal reactions if given by any route 8 , but, of more concern to anaesthetists, hypotension or hypertension if given IV 8, 10 .
A comparison of the effects of prochlorperazine and ondansetron given with induction of anaesthesia on cardiovascular stability, postoperative nausea and vomiting (PONV) and headache appears not to have been studied. This investigation evaluated these effects of IM prochlorperazine 0.2 mg.kg -1 (as per its licence in Europe), IV prochlorperazine 0.1 mg.kg -1 (as per its licence in North America) and IV ondansetron 0.06 mg.kg -1 (as recommended) 11 . A further aim of the study was to determine whether the test drugs would reduce the incidence of PONV by greater than the 46% required by anaesthetists here to justify its routine administration with anaesthesia.
PATIENTS AND METHODS
The study was designed in accordance with the recommendations of Kortilla 12 and prior experience gained during studies of antiemetics in this hospital 13 . Here, non-Arabic-speaking British and Filipino nurses care for Arabic-speaking patients in the postoperative recovery and surgical wards. Each patient was visited on the afternoon before surgery and a history of motion sickness (MS) or previous postoperative nausea and vomiting (PONV) obtained by the author who is conversant in Arabic. However, language constraints precluded query by our Englishspeaking nurses into nausea in the recovery ward.
With Hospital Ethical Committee approval and patient, parent or guardian consent, 220 ASA Grade 1-2 Saudi nationals of all ages presenting for routine nasal surgery (septoplasty, rhinoplasty or septorhinoplasty) were studied between January 1994 and August 1995. In the operating theatre each patient was block randomized to receive saline (as control) or one of the three antiemetic formulations with induction of anaesthesia. Patients were excluded from the study if they had received any antiemetic medication within 24 hours prior to surgery or if pregnant, and were fasted from 0300 hours of the morning of surgery.
Premedication comprised temazepam capsules 0.5 mg.kg -1 to the nearest 10 mg, or temazepam syrup 0.5 mg.kg -1 given orally and EMLA cream applied topically to the dorsum of the left hand approximately 1.5 hours prior to surgery. In theatre, routine monitoring devices (Electrocardiogram: Hewlett Packard 80300A, blood pressure: Dinamap Critikon 1846, oxygen saturation: Ohmeda Biox 3700) were applied, pre-induction heart rate and blood pressure recorded, an intravenous cannula inserted and pre-oxygenation commenced.
Anaesthesia was induced with thiopentone 4.0 mg.kg -1 , atracurium 0.6 mg.kg -1 and nalbuphine 0.2 mg.kg -1 after which the appropriate test drug was administered; saline 2 ml, IM prochlorperazine 0.2 mg.kg -1 , IV prochlorperazine 0.1 mg.kg -1 or IV ondansetron 0.06 mg.kg -1 . The larynx was then sprayed with aerosolized lignocaine 10% 14 , a cuffed endotracheal tube inserted and the pharynx packed with a moist ribbon gauze, while respiration was maintained by intermittent positive pressure ventilation. Heart rate and blood pressures were recorded 1 minute, 4 minutes, 7 minutes and 10 minutes after tracheal intubation to assess the immediate cardiovascular effects of the test drugs, and at five-minute intervals thereafter.
Anaesthesia was maintained with nitrous oxide 67% and isoflurane 0.8% in oxygen. Respiration was controlled using an Ohmeda AV7700 ventilator with a respiratory rate of 8 to 16 breaths per minute, an inspiratory:expiratory ratio of 1:3, a tidal volume of 10 mg.kg -1 and a fresh gas flow of 100 ml.kg -1 .min -1 using the Bain Circuit to maintain an end-tidal carbon dioxide concentration of 4.5-5.0 kPa (Hewlett Packard 47210A Capnometer). Ringer lactate was infused intraoperatively at a rate of 8 ml.kg -1 .h -1 and dextrose saline infused postoperatively at a rate of 2.0 ml.kg -1 .h -1 until oral fluids were tolerated. Prior to commencing surgery, the surgeon injected lignocaine 1% containing 1:200,000 adrenaline (1 ml.10 kg -1 body weight) as appropriate into the mucochondrium of the nasal septum, lateral wall and bridge of the nose. During surgery, after the initial 1, 4, 7 and 10 minute recordings of heart rate and blood pressures, increases in heart rate or systolic arterial pressure >25% of the pre-induction values were treated with injections of esmolol 2.0 to 3.0 mg.kg -1 IV. At the end of surgery, to maintain haemostasis and nasal shape, the surgeon packed both nostrils with Merocel Epistaxis Packs. At this time residual neuromuscular blockade was reversed with neostigmine 0.035 mg.kg -1 and atropine 0.017 mg.kg -1 , the throat pack removed, pharynx suctioned under vision, and the endotracheal tube removed after onset of spontaneous respiration, prior to placing the patient in the lateral (tonsillar) position. Nalbuphine 0.1 mg.kg -1 IV or 0.2 mg.kg -1 , IM para-cetamol 10 mg.kg -1 and prochlorperazine 0.2 mg.kg -1 IM were prescribed to treat postoperative pain, nausea and vomiting in the recovery and postoperative surgical wards, administered at the discretion of nursing staff.
The test drugs were coded (A, B, C or D) and, to ensure blindness, all documentation was appropriately endorsed. Data were recorded on a customized form in the operating theatre, recovery and surgical wards. Prior to induction of anaesthesia note was made of patient details, antiemetic group and baseline heart rate (HR), systolic, diastolic and mean (SAP, DAP, MAP) arterial pressures. At the termination of surgery and anaesthesia the duration of surgery was noted, as well as vomiting or retching immediately following extubation. Nurses in the recovery ward, blind to the test drug given, recorded details of vomiting, retching, extrapyramidal movements (tremors, involuntary movements, muscle spasms, rigidity), antiemetic and analgesic requirements.
During the first 24 hour postoperative period further note was made by nurses, also blind to the test drug given, of any nausea, retching or vomiting reported to them, the time of onset of the complaint and whether the expulsive event was a single or repeated episode. They also recorded details of antiemetic and analgesic drugs given (their nature, time of administration and whether given to treat nausea, retching, vomiting, headache, surgical pain or pyrexia, respectively) and the occurrence of extrapyramidal signs. On the day following surgery the author, blinded to the drug given intraopera-tively, visited the ward to review drug, temperature, fluid balance and nursing records, and to interview each patient and/or their relative or guardian with respect to nausea, retching, vomiting and headache (other than nasal pain related to surgery and presence of nasal pack).
Data were analysed using analysis of variance, Student's t and Chi-squared tests with Yates correction where appropriate. To compare the effects on heart rates and blood pressures, the areas under the time curves for HR, SAP, DAP and MAP were computed for each patient using the trapezoidal rule, and differences between drugs compared using two-way analysis of variance and the technique of Scheffe 15 . Chi-squared tests were used to compare nausea, vomiting and postoperative drug requirement incidences. The effects of the antiemetics in modifying the severity of vomiting was assessed using Chisquared tests after grouping the vomiters in each test group into single and multiple vomiters. Student's t tests were used to compare the mean times of occurrence of postoperative nausea, retching or vomiting. Retches and vomits were analysed collectively. P<0.05 was considered significant. (Table 1) Two-hundred-and-twenty consecutive patients aged between five and 64 years presenting for nasal surgery (septoplasty, rhinoplasty, septorhinoplasty) were studied over an eighteen-month period. The study population comprised four groups of 55 540 A. A. VAN patients which were comparable for gender, age, history of motion sickness or PONV, weight, duration of anaesthesia, time spent in the recovery ward, and need for analgesia and antiemesis in the recovery and postoperative wards. Two male patients, one in each of the IM and IV prochlorperazine groups, were inadvertently not given temazepam as premedication. In the postoperative surgical ward, two male patients, one in the control group and one in the IM prochlorperazine group, who required postoperative analgesia were inadvertently given IM prochlorperazine in conjunction with IM nalbuphine; the latter patient (body weight 51 kg) developed an extrapyramidal reaction after receiving the second dose of IM prochlorperazine, approximately four hours after surgery. The reaction was treated with benztropine IV. One male patient in the IV prochlorperazine group inadvertently received IM pethidine instead of IM nalbuphine to treat postoperative pain. Data pertaining to these five patients were included in the study. (Figure 1 ) Analysis of heart rates and blood pressures did not show any clinically or statistically significant differences between the test drugs within ten minutes of their administration. Specifically, no episodes of hypotension or hypertension were observed after IV injection of prochlorperazine.
RESULTS

Patient Demography and Test Group Comparability
Peroperative Cardiovascular Effects
Postoperative Nausea and Vomiting (Table 2) In the total study population the incidence of nausea per se during the first 24 hour postoperative period occurred with similar frequency in those given placebo (7%), IM prochlorperazine (4%) and IV ondansetron (15%), but most frequently in those given IV prochlorperazine (25%; P<0.01 v. placebo, Chi-squared). Vomiting per se occurred with similar frequency in the placebo (24%) and IM prochlorperazine (18%) groups, but less frequently in those given IV prochlorperazine (7%; P<0.025), Chisquared) and IV ondansetron (4%; P<0.005, Chisquared). The incidence of the combined complaint of nausea with vomiting was reduced from 35% to 15%, 16% and 11% by IM prochlorperazine, IV prochlorperazine and IV ondansetron (P<0.025, P<0.05, P<0.005, Chi-squared) respectively. The incidence of those experiencing no nausea or vomiting was greater than control (35%) only in those given IM prochlorperazine (64%; P<0.005, Chisquared) and IV ondansetron (71%; P<0.0005, 541 
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In those with a positive history of motion sickness or PONV, 12% (1 of 8 patients) in the placebo group, 37% (3 of 8 patients) in the IM prochlorperazine group, 15% (1 of 7 patients) in the IV prochlorperazine group and 50% (4 of 8 patients) in the ondansetron group experienced neither nausea nor vomiting postoperatively. The power of these numbers, however, is insufficient to demonstrate significant differences between these incidences.
The severity of postoperative vomiting was most profound in the control group. Of the 32 patients who vomited, seven (22%) experienced single emetic (SE) episodes while 25 (78%) had multiple emetic (ME) episodes. The ratio of SE:ME vomiters was inverted in those given IM prochlorperazine (SE:ME, 67%:33%, P<0.001 Chi-squared), and reduced, but to insignificant extent in the numbers studied, in those given IV prochlorperazine (SE:ME, 46%:54%) and IV ondansetron (SE:ME, 50%:50%).
Patients given IM prochlorperazine experienced postoperative headache less frequently than those given IV ondansetron (53% v. 71%, P<0.05, Chisquared), but headache occurred with similar frequency in those given placebo (69%), IV prochlorperazine (62%) and IV ondansetron (71%). (Table 3) Any complaint of nausea or vomiting occurred in 65% of patients given placebo, and in 36%, 49% and 29% of those given IM prochlorperazine, IV prochlorperazine and IV ondansetron respectively. The magnitude of these reductions in PONV were 45%, 25% and 55% respectively.
Reduction in Incidence of PONV Produced by Test Drugs
DISCUSSION
This randomized, double-blind, controlled study was conducted to assess the effects on heart rate, blood pressure, PONV and headache of IM prochlorperazine 0.2 mg.kg -1 , IV prochlorperazine 0.1 mg.kg -1 and IV ondansetron 0.06 mg.kg -1 given with induction of anaesthesia to patients undergoing nasal septal surgery. The test drugs produced no adverse effects on heart rate and blood pressure within ten minutes of administration. Intravenous prochlorperazine, paradoxically, was associated with most nausea per se, while it reduced the incidence of vomiting per se. Each antiemetic reduced the incidence of nausea with vomiting, although IV ondansetron appeared to be more efficacious than either prochlorperazine treatment. Intravenous ondansetron did not increase the incidence of postoperative headache compared with placebo, but resulted in a greater incidence of headache than in those given IM prochlorperazine.
Hypertension 8 and hypotension 10 may follow IV injection of prochlorperazine, while IV ondansetron induces no adverse cardiovascular effects 11 . The phenothiazines, of which prochlorperazine is an example, have numerous actions and side-effects. These include central dopaminergic blockade, prolactin secretion, inhibition of adrenocorticotropin secretion in response to stress, cholinergic blockade, depression of central vasomotor reflexes mediated by the hypothalamus or brainstem, alpha-adrenergic blockade and a direct negative inotropic effect on the heart 16 . Variable penetration of these actions may account for the apparently conflicting effects on blood pressure after administration of prochlorperazine IV 8, 10 . The possibility of such events rationalized the choice of the lesser North American approved dose of prochlorperazine (0.1 mg.kg -1 ) for testing via the IV route, rather than the larger European approved parenteral dose (0.2 mg.kg -1 ).
Vomiting after ear, nose and throat surgery performed under general anaesthesia occurs most commonly after middle ear surgery (in about 67% of patients), commonly after nasal surgery (in about 50% of patients) and least frequently after pharyngeal surgery (in about 33% of patients 17, 18 ). The sensory nerve supply of the nose is derived from the ophthalmic division (anterior ethmoidal branch of the nasociliary nerve) and maxillary division (anterior superior branch, the nerve of the pterygoid canal, long sphenopalatine nerve, greater palatine nerve, nasal branches of the sphenopalatine ganglion) of the trigeminal nerve 19 . A variety of reflexes mediated via the vagal nucleus in the brain stem may be invoked by surgical procedures on the head, neck and torso, and result in laryngospasm 20 , bradydysrhythmias [21] [22] [23] [24] [25] [26] [27] and emesis [28] [29] [30] . The former morbidities were not evident in this study; however, the frequency of PONV following nasal surgery may be a manifestation of a trigemini-vagal "naso-emetic" reflex. Nasocardiac, oculoemetic, auriculoemetic and vestibuloemetic 543 
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Anaesthesia and Intensive Care, Vol. 24, No. 5, October 1996 reflexes have been postulated to explain the frequency of dysrhythmia and vomiting associated with nose, squint, bat-ear and middle ear surgery respectively 25, [27] [28] [29] . Frontal headache is frequent and debilitating after nasal septal surgery. In ENT surgery, headache occurs most frequently after nose surgery (in about 75% of patients), less frequently after middle ear surgery (in about 50% of patients) and least frequently after throat surgery (in about 25% of patients 17, 18 ). While mild headache is not uncommon following any general anaesthetic, headache appears to be augmented in patients having nasal surgery by trauma to the nasal cartilages and bones during surgery, and by the presence in the postoperative period of the intranasal pack. The pack is left in situ for 24 hours, and removal alleviates headache. Headache is often accompanied by nausea and vomiting, as in migraine, and pain alone may cause nausea 31 . These myriad factors may contribute to the frequency of PONV associated with nasal surgery.
Ondansetron given as prophylactic antiemetic to patients undergoing chemotherapy and radiotherapy causes headache in 11% of patients 15 . However, its use in anaesthesia appears not to increase the incidence of postoperative headache 2,3 . The possibility that prophylactic ondansetron may increase the incidence of headache after nasal surgery was not realized. However, an unexpected finding was the low frequency of headache in those given IM prochlorperazine, suggesting that IM prochlorperazine may have a special place in the prevention of PONV and headache after nasal surgery.
The question of whether it is unethical to omit the administration of an antiemetic during general anaesthesia, as suggested by Raphael and Norton 3 , is challenging. Only one of thirty-eight anaesthetists in this hospital considers omission of antiemetic unethical. The pronounced reduction in PONV produced by IM prochlorperazine and IV ondansetron in this study illustrates the wisdom of this lone opinion. However, occurrence of an extrapyramidal reaction in a patient given prochlorperazine twice (with anaesthesia and again in the surgical ward in conjunction with parenteral analgesia) suggests that if patients are given prochlorperazine routinely with anaesthesia as prophylaxis against PONV, they are best prescribed an antiemetic devoid of dopaminergic activity, such as ondansetron, for treatment of any subsequent PONV.
The final aim of this study was to attempt to relate the efficacy of the test antiemetics to the efficacy demanded of any antiemetic by anaesthetists to warrant routine administration during anaesthesia. The anaesthetists in this hospital (N=38) require an antiemetic to produce a reduction in the incidence of PONV of 46% to justify its routine use. Ondansetron reduced the incidence of PONV by 55%, thereby meeting this requirement; IM prochlorperazine reduced PONV by 45%, thereby almost meeting this standard; IV prochlorperazine reduced the incidence by 25%, well short of the required standard.
In conclusion, only IV ondansetron 0.06 mg.kg -1 meets the standard required of an antiemetic by anaesthetists in this hospital for routine use during anaesthesia, and was most efficacious in reducing PONV after nasal surgery. Prochlorperazine 0.2 mg.kg -1 IM produced an antiemetic effect which almost met the required standard, but appeared to offer an ancillary advantage of minimizing postoperative headache. Prochlorperazine 0.1 mg.kg -1 IV was the least efficacious, and did not meet the standard required for routine use.
